Mobile apps for dementia patients lack security measures

The lack of cybersecurity in mobile applications meant to assist dementia patients and their caregivers could put patients' personal health information at risk, according to researchers at McLean Hospitals in Belmont, Massachusetts, and clinicians at Harvard Medical School. A study in the American Journal of Geriatric Psychiatry examined app security policies and provided recommendations.

Mobile applications are a convenient way for dementia patients to input information while also providing their caregivers with a tool to check on individuals. This study stated that the patient information stored on these apps is susceptible to hackers due to the lack of security.

“No one using an app for a mental health-related reason should assume that privacy and security measures are in place,” said senior author Ipsit Vahia, MD, medical director of Geriatric Psychiatry Outpatient Services at McLean. “Pay attention to the type of information that they provide to the app, and try to understand what can be done with that information.”

The study analyzed the privacy policies of mobile apps matching the terms "medical + dementia" or "health & fitness + dementia." Of 125 apps, 72 contained user-generated content and only 33 of these apps had privacy policies. Researchers found that, of the apps with policies on individual-level protections, missing information and sharing of data with an outside party were common.

“In order for technology to realize its full potential in mental health, users need to feel confident about the security and privacy of the information that is collected,” concluded Vahia. “Clinicians should educate themselves and their patients about issues related to the data collected.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.